At the same time, both PD-1/PD-L1 monoclonal antibodies and PI3K/AKT/mTOR pathway inhibitors may develop resistance through activation of the bypass pathway, and have drug toxicity and side effects when achieving significant cancer suppression 100. Here, AKT1 is linked to cancer.